Integration and modelling of pharmacokinetic and pharmacodynamic data to optimize dosage regimens in veterinary medicine

Journal of Veterinary Pharmacology and Therapeutics

Volumn 27, Issue 6, 2004, Pages 467-477

  Toutain, P L ^a   Lees, P ^b  

^a CNRS   (France)

^b ROYAL VETERINARY COLLEGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG; NONSTEROID ANTIINFLAMMATORY AGENT;

ANTIMICROBIAL ACTIVITY; CONFERENCE PAPER; DATA ANALYSIS; DOSE TIME EFFECT RELATION; DRUG CONCENTRATION; DRUG DETERMINATION; DRUG DOSE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; SPECIES COMPARISON; TITRIMETRY; VETERINARY MEDICINE;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; MODELS, ANIMAL; MODELS, BIOLOGICAL; VETERINARY DRUGS;

EID: 10844242304     PISSN: 01407783     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2885.2004.00613.x     Document Type: Conference Paper

References (38)

1. Aliabadi, F.S. & Lees, P. (2002) Pharmacokinetics and pharmacokinetic/ pharmacodynamic integration of marbofloxacin in calf serum, exudate and transudate. Journal of Veterinary Pharmacology and Therapeutics, 25, 161-174.
2. Aliabadi, F.S. Ali, B.H., Landoni, M.F. & Lees, P. (2003) Pharmacokinetics and PK-PD modelling of danofloxacin in camel serum and tissue cage fluids. Veterinary Journal, 165, 104-118.
3. Allen, M.C., Shah, T.S. & Day, W.W. (1998) Rapid determination of oral pharmacokinetics and plasma free fraction using cocktail approaches: methods and application. Pharmaceutical Research, 15, 93-97.
4. Anonymous (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clinical Pharmacology and Therapeutics, 69, 89-95.
5. Colburn, W.A. (2000) Optimizing the use of biomarkers, surrogate endpoints, and clinical endpoints for more efficient drug development. Journal of Clinical Pharmacology, 40, 1419-1427.
6. Craig, W.A. (1998) Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clinical Infectious Diseases, 26, 11-12.
7. Dayneka, N.L., Garg, V. & Jusko, W.J. (1993) Comparison of four basic models of indirect pharmacodynamic responses. Journal of Pharmacokinetics and Biopharmaceutics, 21, 457-478.
8. Holford, N.H.G. (1992) Parametric models of the time course of drug action. In The in vivo Study of Drug Action. Eds van Boxtel, C.J., Holford, N.H.G. & Danhof, M. pp. 61-69. Elsevier Science Publishers, the Netherlands.
9. Holford, N.H. & Sheiner, L.B. (1981) Pharmacokinetic and pharmacodynamic modeling in vivo. CRC Critical Reviews in Bioengineering, 5, 273-322.
10. Hop, C.E., Wang, Z., Chen, Q. & Kwei, G. (1998) Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. Journal of Pharmaceutical Sciences, 87, 901-903.
11. Hyatt, J.M., McKinnon, P.S., Zimmer, G.S. & Schentag, J.J. (1995) The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clinical Pharmacokinetics, 28, 143-160.
12. Landoni, M.F. & Lees, P. (1995) Pharmacokinetics and pharmacodynamics of ketoprofen enantiomers in calves. Chirality, 7, 586-597.
13. Landoni, M.F., Cunningham, F.M. & Lees, P. (1995) Determination of pharmacokinetics and pharmacodynamics of flunixin in calves by use of pharmacokinetic/pharmacodynamic modeling. American Journal of Veterinary Research, 56, 786-794.
14. Landoni, M.F., Cunningham, F.M. & Lees, P. (1996) Pharmacokinetics and pharmacodynamics of tolfenamic acid in calves. Research in Veterinary Science, 61, 26-32.
15. Lees, P. (2003) Pharmacology of drugs used to treat osteoarthritis in veterinary practice. Inflammopharmacology, 11, 385-399.
16. Lees, P. & Shojaee Aliabadi, F. (2002) Rational dosing of antimicrobial drugs: animals versus humans. International Journal of Antimicrobial Agents, 19, 269-284.
17. Lees, P., McKellar, Q., May, S.A. & Ludwig, B. (1994) Pharmacodynamics and pharmacokinetics of carprofen in the horse. Equine Veterinary Journal, 26, 203-208.
18. Lees, P., Cunningham, F.M. & Elliott, J. (2004a) Principles of pharmacodynamics and their applications in veterinary pharmacology. Journal of Veterinary Pharmacology and Therapeutics, 27, 397-414.
19. Lees, P., Giraudel, J., Landoni, M.F. & Toutain, P.L. (2004b) PK-PD integration and PK-PD modeling of non-steroidal anti-inflammatory drugs: principles and applications in veterinary pharmacology. Journal of Veterinary Pharmacology and Therapeutics, 27, 491-502.
20. Lees, P., Aliabadi, F.S. & Toutain, P.L. (2004c) PK-PD modeling: an alternative to dose titration studies for antimicrobial drug dosage selection. Regulatory Affairs Journal, 15, 175-180.
21. Leggett, J.E., Ebert, S., Fantin, B. & Craig, W.A. (1991) Comparative dose effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models. Scandinavian Journal of Infectious Diseases, Suppl. 74, 179-184.
22. McKellar, Q., Sanchez, S.F. & Jones, D.G. (2004) Pharmacokinetic/ pharmacodydnamic relationships of antimicrobial drugs used in veterinary medicine. Journal of Veterinary Pharmacology and Therapeutics, 27, 503-514.
23. Moore, R.D., Smith, C.R. & Lietman, P.S. (1984) Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. American Journal of Medicine, 77, 657-662.
24. Neubig, R.R., Spedding, M., Kenakin, T. & Christopoulos, A. (2003) International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on Terms and Symbols in Quantitative Pharmacology. Pharmacological Reviews, 55, 597-606.
25. Schentag, J.J. (1989) Clinical significance of antibiotic tissue penetration. Clinical Pharmacokinetics, 16 (Suppl. 1), 25-31.
26. Schentag, J.J., Swanson, D.J. & Smith, I.L. (1985) Dual individualization: antibiotic dosage calculation from the integration of in-vitro pharmacodynamics and in-vivo pharmacokinetics. Journal of Antimicrobial Chemotherapy, 15 (Suppl. A) 47-57.
27. Sheiner, L.B., Hashimoto, Y. & Beal, S.L. (1991) A simulation study comparing designs for dose ranging. Statistics in Medicine, 10, 303-321.
28. Toutain, P.L. (2002) Pharmacokinetics/pharmacodynamics integration in drug development and dosage regimen optimization for veterinary medicine. AAPS Pharmaceutical Sciences, 4: http://www.aapspharmsci. org/ps0404/ps040438/ ps040438.pdf [accessed 1 December 2004].
29. Toutain, P.L. (2003) Pharmacokinetics/pharmacodynamics integration in dosage regimen optimization for veterinary medicine. In: 9th International Congress of the European Association for Veterinary Pharmacology and Toxicology. Lisbon, Portugal, July 13-18, 2003. Eds Fontes, M.E. & Lees, P. Journal of Veterinary Pharmacology and Therapeutics, 26 (Suppl. 1), 1-8.
30. Toutain, P.L. & Bousquet-Melou, A. (2004) Plasma clearance. Journal of Veterinary Pharmacology and Therapeutics, 27, 415-425.
31. Toutain, P.L. & Lassourd, V. (2002a) Pharmacokinetic/pharmacodynamic approach to assess irrelevant plasma or urine drug concentrations in postcompetition samples for drug control in the horse. Equine Veterinary Journal, 34, 242-249.
32. Toutain, P.L. & Lassourd, V. (2002b) Pharmacokinetics/pharmacodynamic assessment of irrelevant drug concentrations in horse plasma or urine for a selection of drugs. In 14th International Conference of Racing Analysts and Veterinarians. Eds Hill, D.W. & Hill, W.T. pp. 19-27. RandW Publication Ltd, Orlando, FL, USA.
33. Toutain, P.L. & Lefebvre, H.P. (2004) Pharmacokinetics and pharmacokinetic/pharmacodynamic relationships for angiotensin-converting-enzyme (ACE) inhibitors. Journal of Veterinary Pharmacology and Therapeutics, 27, 515-525.
34. Toutain, P.L., Autefage, A., Legrand, C. & Alvinerie, M. (1994) Plasma concentrations and therapeutic efficacy of phenylbutazone and flunixin meglumine in the horse: pharmacokinetlc/pharmacodynamic modelling. Journal of Veterinary Pharmacology and Therapeutics, 17, 459-469.
35. Toutain, P.L., Lefebvre, H.P. & King, J.N. (2000) Benazeprilat disposition and effect in dogs revisited with a pharmacokinetic/pharmacodynamic modeling approach. Journal of Pharmacology and Experimental Therapeutics, 292, 1087-1093.
36. Toutain, P.L., Cester, C.C., Haak, T. & Laroute, V. (2001) A pharmacokinetic/pharmacodynamic approach vs. a dose titration for the determination of a dosage regimen: the case of nimesulide, a Cox-2 selective nonsteroidal anti-inflammatory drug in the dog. Journal of Veterinary Pharmacology and Therapeutics, 24, 43-55.
37. Toutain, P.L., del Castillo, J.R.E. & Bousquet-Mélou, A. (2002) The pharmacokinetic-pharmacodynamic approach to a rational dosage regimen for antibiotics. Research in Veterinary Science, 73, 105-114.
38. Warner, T.D., Giuliano, F., Vojnovic, I., Bukasa, A., Mitchell, J.A. & Vane, J.R. (1999) Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proceedings of the National Academic of Sciences, 96, 7563-7568.